- Home
- PLRX vs SERA Comparison
PLRX vs SERA Comparison
Compare PLRX & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLRX | SERA |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.9M | 77.2M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PLRX | SERA |
|---|---|---|
| Price | $1.28 | $1.90 |
| Analyst Decision | Hold | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $2.67 | N/A |
| AVG Volume (30 Days) | ★ 620.9K | 66.3K |
| Earning Date | 06-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.97 | 14.66 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $77,000.00 |
| Revenue This Year | N/A | $25.84 |
| Revenue Next Year | N/A | $715.79 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.09 | $1.37 |
| 52 Week High | $1.95 | $4.20 |
Technical Indicators
Market Signals| Indicator | PLRX | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 50.82 | 32.39 |
| Support Level | $1.12 | $1.80 |
| Resistance Level | $1.36 | $2.00 |
| Average True Range (ATR) | 0.07 | 0.21 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 31.71 | 12.77 |
Price Performance
Historical ComparisonAbout PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.